Viewing Study NCT04519151


Ignite Creation Date: 2025-12-24 @ 11:49 PM
Ignite Modification Date: 2025-12-25 @ 9:43 PM
Study NCT ID: NCT04519151
Status: RECRUITING
Last Update Posted: 2023-06-08
First Post: 2020-08-04
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Sponsor: Sheba Medical Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module